European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Hemlibra, emicizumab, Date of authorisation: 23/02/2018, Revision: 21, Status: Authorised

Submitted by Anonymous (not verified) on 27 October 2026 - 16:40

Human medicines European public assessment report (EPAR): Hemlibra, emicizumab, Date of authorisation: 23/02/2018, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 17, Status: Authorised

Submitted by Anonymous (not verified) on 27 October 2026 - 16:32

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Vocabria, cabotegravir, Date of authorisation: 17/12/2020, Revision: 18, Status: Authorised

Submitted by Anonymous (not verified) on 27 October 2026 - 16:28

Human medicines European public assessment report (EPAR): Vocabria, cabotegravir, Date of authorisation: 17/12/2020, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Sitagliptin SUN, sitagliptin fumarate, Date of authorisation: 09/12/2021, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 27 October 2026 - 16:20

Human medicines European public assessment report (EPAR): Sitagliptin SUN, sitagliptin fumarate, Date of authorisation: 09/12/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Brimica Genuair, aclidinium,formoterol fumarate dihydrate, Date of authorisation: 19/11/2014, Revision: 17, Status: Authorised

Submitted by Anonymous (not verified) on 27 October 2026 - 16:10

Human medicines European public assessment report (EPAR): Brimica Genuair, aclidinium,formoterol fumarate dihydrate, Date of authorisation: 19/11/2014, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Bretaris Genuair, aclidinium bromide, Date of authorisation: 20/07/2012, Revision: 21, Status: Authorised

Submitted by Anonymous (not verified) on 27 October 2026 - 16:08

Human medicines European public assessment report (EPAR): Bretaris Genuair, aclidinium bromide, Date of authorisation: 20/07/2012, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Glivec, imatinib, Date of authorisation: 07/11/2001, Revision: 52, Status: Authorised

Submitted by Anonymous (not verified) on 27 October 2026 - 15:38

Human medicines European public assessment report (EPAR): Glivec, imatinib, Date of authorisation: 07/11/2001, Revision: 52, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Vafseo, vadadustat, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000245403

Submitted by Anonymous (not verified) on 27 October 2026 - 14:01

Opinion/decision on a Paediatric investigation plan (PIP): Vafseo, vadadustat, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000245403

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More